Nicotinamide drives T cell activation in the mammary tumor microenvironment

Yang Hu, Norma Bloy, Olivier Elemento, Aitziber Buqué

Research output: Contribution to journalLetterpeer-review

1 Scopus citations

Abstract

Nicotinamide (NAM, a variant of vitamin B3) has recently been shown to accelerate the activation of human CD4+ and CD8+ T cells exposed to repeated CD3/CD28 agonism in vitro. Here, we demonstrate that T cells infiltrating mouse mammary carcinomas that are therapeutically controlled by NAM also express multiple markers of late-stage activation. Taken together, these findings lend additional support to the notion that the antineoplastic effects of NAM involve at least some degree of restored cancer immunosurveillance.

Original languageEnglish
Article number251
JournalJournal of Translational Medicine
Volume20
Issue number1
DOIs
StatePublished - May 3 2022
Externally publishedYes

Keywords

  • CTLA4
  • Immune checkpoint inhibitors
  • Immunotherapy
  • LAG3
  • PD-1
  • TIM-3
  • Niacinamide/pharmacology
  • Tumor Microenvironment
  • CD8-Positive T-Lymphocytes
  • Animals
  • Lymphocytes, Tumor-Infiltrating
  • Programmed Cell Death 1 Receptor
  • Mice

Fingerprint

Dive into the research topics of 'Nicotinamide drives T cell activation in the mammary tumor microenvironment'. Together they form a unique fingerprint.

Cite this